Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation

Zhibo Gai, Michele Visentin, Ting Gui, Lin Zhao, Wolfgang E. Thasler, Stephanie Häusler, Ivan Hartling, Alessio Cremonesi, Christian Hiller and Gerd A. Kullak-Ublick
Molecular Pharmacology August 2018, 94 (2) 802-811; DOI: https://doi.org/10.1124/mol.117.111047
Zhibo Gai
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., M.V., S.H., C.H., G.A.K.-U.); Experiment Center, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China (T.G.); Department of Endocrinology, Chinese PLA 309 Hospital, Peking, China (L.Z.); Department of General and Visceral Surgery, Rotkreuzklinikum Munich, Munich, Germany (W.E.T.); Department of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, Zurich, Switzerland (I.H., A.C.); and Mechanistic Safety, Novartis Global Drug Development, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Visentin
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., M.V., S.H., C.H., G.A.K.-U.); Experiment Center, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China (T.G.); Department of Endocrinology, Chinese PLA 309 Hospital, Peking, China (L.Z.); Department of General and Visceral Surgery, Rotkreuzklinikum Munich, Munich, Germany (W.E.T.); Department of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, Zurich, Switzerland (I.H., A.C.); and Mechanistic Safety, Novartis Global Drug Development, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ting Gui
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., M.V., S.H., C.H., G.A.K.-U.); Experiment Center, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China (T.G.); Department of Endocrinology, Chinese PLA 309 Hospital, Peking, China (L.Z.); Department of General and Visceral Surgery, Rotkreuzklinikum Munich, Munich, Germany (W.E.T.); Department of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, Zurich, Switzerland (I.H., A.C.); and Mechanistic Safety, Novartis Global Drug Development, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lin Zhao
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., M.V., S.H., C.H., G.A.K.-U.); Experiment Center, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China (T.G.); Department of Endocrinology, Chinese PLA 309 Hospital, Peking, China (L.Z.); Department of General and Visceral Surgery, Rotkreuzklinikum Munich, Munich, Germany (W.E.T.); Department of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, Zurich, Switzerland (I.H., A.C.); and Mechanistic Safety, Novartis Global Drug Development, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang E. Thasler
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., M.V., S.H., C.H., G.A.K.-U.); Experiment Center, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China (T.G.); Department of Endocrinology, Chinese PLA 309 Hospital, Peking, China (L.Z.); Department of General and Visceral Surgery, Rotkreuzklinikum Munich, Munich, Germany (W.E.T.); Department of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, Zurich, Switzerland (I.H., A.C.); and Mechanistic Safety, Novartis Global Drug Development, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Häusler
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., M.V., S.H., C.H., G.A.K.-U.); Experiment Center, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China (T.G.); Department of Endocrinology, Chinese PLA 309 Hospital, Peking, China (L.Z.); Department of General and Visceral Surgery, Rotkreuzklinikum Munich, Munich, Germany (W.E.T.); Department of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, Zurich, Switzerland (I.H., A.C.); and Mechanistic Safety, Novartis Global Drug Development, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivan Hartling
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., M.V., S.H., C.H., G.A.K.-U.); Experiment Center, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China (T.G.); Department of Endocrinology, Chinese PLA 309 Hospital, Peking, China (L.Z.); Department of General and Visceral Surgery, Rotkreuzklinikum Munich, Munich, Germany (W.E.T.); Department of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, Zurich, Switzerland (I.H., A.C.); and Mechanistic Safety, Novartis Global Drug Development, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessio Cremonesi
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., M.V., S.H., C.H., G.A.K.-U.); Experiment Center, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China (T.G.); Department of Endocrinology, Chinese PLA 309 Hospital, Peking, China (L.Z.); Department of General and Visceral Surgery, Rotkreuzklinikum Munich, Munich, Germany (W.E.T.); Department of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, Zurich, Switzerland (I.H., A.C.); and Mechanistic Safety, Novartis Global Drug Development, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Hiller
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., M.V., S.H., C.H., G.A.K.-U.); Experiment Center, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China (T.G.); Department of Endocrinology, Chinese PLA 309 Hospital, Peking, China (L.Z.); Department of General and Visceral Surgery, Rotkreuzklinikum Munich, Munich, Germany (W.E.T.); Department of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, Zurich, Switzerland (I.H., A.C.); and Mechanistic Safety, Novartis Global Drug Development, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerd A. Kullak-Ublick
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (Z.G., M.V., S.H., C.H., G.A.K.-U.); Experiment Center, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China (T.G.); Department of Endocrinology, Chinese PLA 309 Hospital, Peking, China (L.Z.); Department of General and Visceral Surgery, Rotkreuzklinikum Munich, Munich, Germany (W.E.T.); Department of Clinical Chemistry and Biochemistry, University Children’s Hospital Zurich, Zurich, Switzerland (I.H., A.C.); and Mechanistic Safety, Novartis Global Drug Development, Basel, Switzerland (G.A.K.-U.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Arachidonic acid metabolism-related gene expression levels in the liver from mice fed an HFD. Scheme of the main arachidonic acid bioactive products (A). Heat map generated from NGS data of mRNA profiling of genes involved in arachidonic acid metabolism. Blue and red colors indicate downregulation and upregulation in the HFD group, respectively (B). Spearman correlation matrices within the HFD group, between hepatic mRNA expression levels of EET-related enzymes and those of canonical genes involved in inflammation and fibrogenesis (C). CYP2C8 mRNA expression level in liver biopsies from NAFLD and non-NAFLD patients. n = 5/group. Data are means ±S.D., Student’s t test, *<0.05 (D). CYP2C8 mRNA expression in human liver biopsies and NAFLD score correlation, as determined by histology. Data were normalized for the lowest CYP2C8 mRNA expression value (shown in red) (E).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Inhibitory effect of OCA on HFD-induced NASH. Serum ALT (A), serum hydroxyproline (B), hepatic NAFLD score (C). Hepatic mRNA levels of mCol1a1 (D), mCcl2 (E), mIcam (F), mTnfa (G), mIl1b (H) and mIl6 (I). n ≥ 6 mice/group. Data are means ± S.D., one-way ANOVA < 0.05, Tukey’s test, *<0.05. Representative images of immunostaining for the macrophage marker MAC387 (J) and CD4 (K) in liver sections from chow (a), HFD (b) and HFD+OCA (c) groups.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Regulatory effect of OCA on arachidonic acid metabolism. Heat map of mRNA profiling of selected genes involved in arachidonic acid metabolism. The relative expression values of each target gene were measured in the chow, HFD, and HFD + OCA mice, normalized for the expression of β-actin and then expressed as HFD:chow (HFD) or HFD + OCA:chow (HFD + OCA) ratio. Each column represents an individual sample. Blue and red colors indicate downregulation and upregulation, respectively (A). Relative hepatic mRNA levels of arachidonate partitioning genes (B–E). Serum levels of LTB4 (F) and 14,15-EET (G). Ratio between serum LTB4 and serum 14,15-EET (H). Urinary levels of 14,15-DHET (I). Data are means ± S.D., one-way ANOVA < 0.05, Tukey’s test, *<0.05. n ≥ 6 mice/group.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Effect of FXR activation on arachidonate metabolism and FFA-induced monocyte migration. Representative images showing crystal violet staining of THP-1 cells onto a 3-µm pore polycarbonate membrane insert upon exposure to the medium of Huh7 cells treated with 50 μM FFA in the presence or absence of 2 μM OCA (a-d) (A). Relative migration score (B). Levels of LTB4 (C), 14,15-EET (D), LTB4/14,15-EET ratio (E), and 14,15-DHET (F) in the medium of Huh7 cells exposed to 50 μM FFA in the presence or absence of 2 μM OCA. mRNA levels of CYP2C8 in Huh7 cells with the different treatments (G). Data are means ± S.D., one-way ANOVA < 0.05, Tukey’s test, *<0.05. n = 4/group.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Effect of NF-kB and CYP450 epoxygenase modulation on FFA-induced migration. Migration score of THP-1 cells in the medium of Huh7 cells treated with 50 μM FFA in combination with 10 μM NF-kB inhibitor benzoxathiole derivative (BOT) (A) or 20 μM rifampicin (B). The effect of 50 μM FFA on the migration of THP-1 cells in the medium of Huh7 cells transiently overexpressing Cyp2c29 (C). mRNA expression levels of NF-kB target genes in Huh7 cells exposed to 50 μM FFA and 20 μM rifampicin (D and E). The mRNA expression levels of NF-kB target genes in Huh7 cells transiently overexpressing cyp2c29 and exposed to 50 μM FFA (F and G). Data represent the mean ± S.D., one-way ANOVA < 0.05, Tukey’s test, *<0.05. n = 3/group.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Effect of gemfibrozil on OCA-mediated anti-inflammatory action. Representative images showing crystal-violet staining of THP-1 cells onto a 3-µm pore polycarbonate membrane insert upon exposure to the medium of Huh7 cells treated with 50 μM FFA in the presence or absence of 2 μM of OCA and 100 μM of GM (a-f) (A). Relative migration score (B). Levels of LTB4 (C), 14,15-EET (D) in the medium of Huh7 cells exposed to 50 μM FFA in the presence or absence of 2 μM OCA and 100 μM GM). *<0.05.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Model of the FXR-mediated repression of NF-κB signaling. Increased LTB4 levels and decreased and EET levels promote NF-κB signaling, which triggers hepatic inflammation (A). Transactivation of P450 epoxygenase expression and EET synthesis by FXR, which, in turn, inhibits the NF-κB signaling (B).

Tables

  • Figures
  • Additional Files
    • View popup
    Table 1

    Selected differentially expressed genes in liver from chow mice and high-fat diet (HFD) mice

    Numbers in parentheses indicate gene expression levels quantified as log2 of fold changes.

    Pathways Differentially Regulated in HFD Liver
    Lipid metabolism
     Gpat2 (0.7), Abhd4 (0.6), Acacb (1.2), Acsl5 (0.6), Acsm3 (1.0), Bche (0.7), Echs1 (0.5), Hadh (0.9), Acaca (0.7)
     TGFb-induced EMT
     TGFb2 (0.8), Jun (1.7), Fos (1.48), Fosl1 (0.8), Mmp2 (1.0), Edn1 (1.4), Vim (0.8), Ocln (−0.8)
    Fatty acid metabolism
     Cd74 (1.5), Elovl5 (1.6), Aacs (2.0), Acaa1b (1.3), Acacb (1.2), Acsf3 (0.7), Acsl5 (0.6), Acsm3 (1.0), Ch25h (1.3), Elovl2 (0.9), Echs1 (0.5), Fads1 (0.8), Fads2 (1.3), Fasn (1.5), Gpam (0.9), Hao2 (3.0), Hadh (0.9), Hsd17b4 (0.5), Myo5a (1.0), Elovl6 (0.9), Acaca (0.7), Scd1 (1.6), Scd2 (1.0), Scd3 (1.5)
    Arachidonic acid metabolism
     Cbr3 (1.6), Pla2g6 (0.9), Cyp2c29 (−1.2), Cyp2c37 (−0.8), Cyp2c39 (−0.7), Cyp2c44 (−1.0), Cyp2c50 (−0.7), Cyp2c54 (−1.2), Cyp2c55 (−1.3), Cyp2c70 (−1.6), Cyp4f14 (−0.7)

Additional Files

  • Figures
  • Tables
  • Data Supplement

    • Supplemental Figures -

      Supplemental Figure 1 - NASH assessment in mice fed a HFD

      Supplemental Figure 2 - Arachidonic acid metabolism in mice fed a HFD

      Supplemental Figure 3 - Effect of OCA on HFD-induced NASH

      Supplemental Figure 4 - Effect of OCA on the expression of FXR target genes in Huh7 cells

      Supplemental Figure 5 - Impact of FXR activation on FFA-induced monocyte migration and EET metabolism-related gene expression levels in primary cultured hepatocytes from mouse (A and B) and human (C and D)

      Supplemental Figure 6 - Effect of the co-incubation with OCA and the FXR antagonist z-Guggulsterone (Gu) on FXR activation and FFA-induced monocyte migration

      Supplemental Figure 7 - Effect of OCA, Gemfibrozil (GM) or Rifampicin (Rifa) on THP-1 cell migration induced by serum or exogenous LTB4

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 94 (2)
Molecular Pharmacology
Vol. 94, Issue 2
1 Aug 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

FXR and Arachidonic Acid Metabolism

Zhibo Gai, Michele Visentin, Ting Gui, Lin Zhao, Wolfgang E. Thasler, Stephanie Häusler, Ivan Hartling, Alessio Cremonesi, Christian Hiller and Gerd A. Kullak-Ublick
Molecular Pharmacology August 1, 2018, 94 (2) 802-811; DOI: https://doi.org/10.1124/mol.117.111047

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

FXR and Arachidonic Acid Metabolism

Zhibo Gai, Michele Visentin, Ting Gui, Lin Zhao, Wolfgang E. Thasler, Stephanie Häusler, Ivan Hartling, Alessio Cremonesi, Christian Hiller and Gerd A. Kullak-Ublick
Molecular Pharmacology August 1, 2018, 94 (2) 802-811; DOI: https://doi.org/10.1124/mol.117.111047
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cysteine151 in Keap1 Drives CDDO-Me Pharmacodynamic Action
  • Allosteric Modulation of Metabotropic Glutamate Receptor 1
  • Mechanism of Selective Action of Paraherquamide A
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics